ZNF207

Across TCGA pan-cancer cohorts, ZNF207 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF207 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZNF207 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF207 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, LUSC, and THCA are the cancer types where ZNF207 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	1.000	0.606	.018	14	view →
LUSC	OS	Median	III,IV	0.287	0.687	.029	6	view →
THCA	DFS	Median	All	0.224	0.843	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF207–BLCA (DFS)

Open the BLCA breakdown →